Evidence map›Paper›PMID 38017325›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

MET-receptor targeted fluorescent imaging and spectroscopy to detect multifocal papillary thyroid cancer.

Madelon J H Metman, Pascal K C Jonker, Luc H J Sondorp, Bettien M van Hemel, Mark S Sywak, Anthony J Gill, Liesbeth Jansen, Paul J van Diest, Tessa M van Ginhoven, Clemens W G M Löwik and 7 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03470259 (Detection of Thyroid Cancer and Central Lymph Node Metastases Using EMI-137 Enhanced Molecular Fluorescent Guided Imaging), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03470259 phase1completednot on this map

Detection of Thyroid Cancer and Central Lymph Node Metastases Using EMI-137 Enhanced Molecular Fluorescent Guided Imaging: a Multicentre Feasibility and

TypeinterventionalSponsorUniversity Medical Center GroningenRan2018 to 2019Enrolled19ConditionsPapillary Thyroid Cancer, Lymph Node MetastasesArmsIV adminstration of EMI-137, Multispectral Fluorescence Reflectance Imaging, Spectroscopy
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Targeting c-MET for Endoscopic Detection of Dysplastic Lesions within Barrett's Esophagus Using EMI-137 Fluorescence Imaging.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  7. Article
  8. Article
  9. Fiat lux: the dawn of fluorescence in molecular imaging of differentiated thyroid cancer.European journal of nuclear medicine and molecular imaging · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 3 countries.

Madelon J H MetmanDepartment of Surgery, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
Pascal K C JonkerDepartment of Surgery, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
Luc H J SondorpDepartment of Surgery, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
Bettien M van HemelDepartment of Pathology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Mark S SywakDepartment of Endocrine Surgery and Surgical Oncology, Royal North Shore Hospital, St Leonards, Australia.
Anthony J GillNSW Health Pathology, Department of Anatomical Pathology, Royal North Shore Hospital, St Leonards, Australia.
Liesbeth JansenDepartment of Surgery, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.
Paul J van DiestDepartment of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.
Tessa M van GinhovenDepartment of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Clemens W G M LöwikDepartment of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands.
Anh H NguyenDepartment of Pathology, Erasmus MC, Rotterdam, the Netherlands.
Dominic J RobinsonDepartment of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Gooitzen M van DamDepartment of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Thera P LinksDepartment of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Rob P CoppesDepartment of Biomedical Sciences of Cell & Systems - Section Molecular Cell Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Rudolf S N FehrmannDepartment of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Schelto KruijffDepartment of Surgery, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands. s.kruijff@umcg.nl.ORCID 0000-0002-5151-7320
University Medical Center Groningen · NLErasmus MC · NLErasmus MC Cancer Institute · NLRoyal North Shore Hospital · AUThe University of Sydney · AUUniversity Medical Center Utrecht · NL

Funding

KWF Kankerbestrijding project number 10851
6 · The paper itself

Abstract

purposeMultifocal disease in PTC is associated with an increased recurrence rate. Multifocal disease (MD) is underdiagnosed with the current gold standard of pre-operative ultrasound staging. Here, we evaluate the use of EMI-137 targeted molecular fluorescence-guided imaging (MFGI) and spectroscopy as a tool for the intra-operative detection of uni- and multifocal papillary thyroid cancer (PTC) aiming to improve disease staging and treatment selection.

methodsA phase-1 study (NCT03470259) with EMI-137 was conducted to evaluate the possibility of detecting PTC using MFGI and quantitative fiber-optic spectroscopy.

resultsFourteen patients underwent hemi- or total thyroidectomy (TTX) after administration of 0.09 mg/kg (n = 1), 0.13 mg/kg (n = 8), or 0.18 mg/kg (n = 5) EMI-137. Both MFGI and spectroscopy could differentiate PTC from healthy thyroid tissue after administration of EMI-137, which binds selectively to MET in PTC. 0.13 mg/kg was the lowest dosage EMI-137 that allowed for differentiation between PTC and healthy thyroid tissue. The smallest PTC focus detected by MFGI was 1.4 mm. MFGI restaged 80% of patients from unifocal to multifocal PTC compared to ultrasound.

conclusionEMI-137-guided MFGI and spectroscopy can be used to detect multifocal PTC. This may improve disease staging and treatment selection between hemi- and total thyroidectomy by better differentiation between unifocal and multifocal disease.

trial registrationNCT03470259.

Indexed as

Proto-Oncogene Proteins c-metThyroid Cancer, PapillaryThyroid NeoplasmsAdultAgedCarcinoma, PapillaryFemaleHumansMaleMiddle AgedOptical ImagingProto-Oncogene Proteins c-metMolecular fluorescence–guided imagingMultifocalityPapillary thyroid cancerSpectroscopy

Identifiers

PMID38017325
PMCPMC11178647
OpenAlexW4389151883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.